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Abstract
Background: Gene expression profiling of human breast tumors has uncovered several molecular signatures that
can divide breast cancer patients into good and poor outcome groups. However, these signatures typically
comprise many genes (~50-100), and the prognostic tests associated with identifying these signatures in patient
tumor specimens require complicated methods, which are not routinely available in most hospital pathology
laboratories, thus limiting their use. Hence, there is a need for more practical methods to predict patient survival.
Methods: We modified a feature selection algorithm and used survival analysis to derive a 2-gene signature that
accurately predicts breast cancer patient survival.
Results: We developed a tree based decision method that segregated patients into various risk groups using
KIAA0191 expression in the context of E2F1 expression levels. This approach led to highly accurate survival
predictions in a large cohort of breast cancer patients using only a 2-gene signature.
Conclusions: Our observations suggest a possible relationship between E2F1 and KIAA0191 expression that is
relevant to the pathogenesis of breast cancer. Furthermore, our findings raise the prospect that the practicality of
patient prognosis methods may be improved by reducing the number of genes required for analysis. Indeed, our
E2F1/KIAA0191 2-gene signature would be highly amenable for an immunohistochemistry based test, which is
commonly used in hospital laboratories.
Background
Traditionally, a variety of clinical and histopathological
characteristics have been employed to make predictions
regarding the potential clinical outcomes of breast
cancer patients. However, the advent of gene expression
profiling technologies has enabled the use of molecular
signatures to provide improved predictions of clinical
outcome over traditional methods [1-5]. These signa-
tures typically comprise many genes and require profil-
ing their expression by measuring the abundance of
their respective mRNA transcripts [3-5]. A major issue
concerning the use of molecular signatures to provide
prognostic information for cancer patients, is that tran-
script profiling tests require personnel with specialized
training, as well as expensive reagents and equipment.
These platforms are not routinely available in hospital
pathology laboratories, which necessitates shipping
tumor samples to an appropriately equipped laboratory,
thereby increasing the time and cost of carrying out
these tests. We hypothesize that identifying gene signa-
tures that comprise 2-3 genes would enable the develop-
ment of highly practical immunohistochemical based
tests, which are commonly used in hospital based
pathology laboratories.
Because the expression of proliferation associated
genes has been shown to group breast cancer patients
into good and poor risk groups [1], we sought to iden-
tify genes whose expression could increase the predictive
accuracy of the proliferation gene, E2F1. E2F1 encodes a
transcription factor that regulates the expression of
target genes whose products participate in numerous
processes such as DNA replication, mitotic check point,
mitosis, DNA damage checkpoints, and DNA repair
[6-8]. Generally, E2F1 is bound to and functionally inac-
tivated by pRB; however, proliferative signals induce the
phosphorylation of pRB by cyclinD/CDK4/6 complexes
leading to the dissociation of pRB from E2F1, and the
subsequent activation of E2F1 target genes [7]. In line
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ious other members of the E2F gene family forces the
re-entry of quiescent cells into S phase [9].
Using an algorithm we published recently [10], we
f o u n dt h a tt h ee x p r e s s i o no fKIAA0191 transcripts can
be used in conjunction with those of E2F1 to more
accurately predict breast cancer patient survival than
does E2F1 expression alone. KIAA0191, commonly
known as TUT4 or ZCCHC11, encodes a canonical poly
(A) polymerase, whose function involves the polyadeny-
lation of pre-mRNA in the nucleus [11]. KIAA0191 has
been shown to work in concert with Lin28 to suppress
microRNA biogenesis through uridylation of pre-micro-
RNA. Importantly, KIAA0191 function has not been
previously linked to E2F1. Here we demonstrate that the
expression of KIAA0191 transcripts alone is not related
to breast cancer patient survival. However, in the con-
text of average to high expression of E2F1 transcript
levels, high KIAA0191 expression was linked to poor
breast cancer patient prognosis, whereas low KIAA0191
expression was linked to good outcome for these
patients. Interestingly, our study identified a potentially
novel functional relationship between E2F1 and
KIAA0191, which may be of clinical relevance to breast
cancer patients.
Methods
Microarray and clinical data
We used data from the Stanford microarray repository
(downloaded from http://microarray-pubs.stanford.edu/
wound_NKI/explore.html) for our analyses. We also
downloaded a matrix containing clinical data for the
patients that provided samples for the microarray pro-
files used in the present study from the same location.
We created a master data matrix by combining the gene
expression profiles with indices for survival and metasta-
sis for each patient. Patients included within this cohort
had either stage I or II breast cancer and were less than
53 years of age. The prevalence of lymph-node positive
and lymph-node negative disease was approximately
50% for each, respectively.
Identification of genes that enhance the predictive power
of E2F1
To discover genes that might improve the capacity of
E2F1 transcript levels to predict the prognosis of human
breast cancer patients, we first ranked the level of gene
expression for each gene in every patient’s breast tumor
as described previously [10]. We then adapted a similar
approach to that we used previously, but instead of
searching for genes whose expression was related to
patient survival [10], we modified the algorithm to
search for genes whose expression was predictive of
patient survival in combination with that of E2F1. We
then ranked all the genes present in the expression pro-
files using a scoring technique published previously [10].
Survival and statistical analysis
Unless otherwise indicated all survival analyses and
associated statistical tests were completed using
GraphPad Prism 5™ software. Harrell’s concordance-
index (C-index) was calculated using the Hmisc pack-
age in R [12].
Selection of random genes
Randomly selected genes were obtained by using a ran-
dom number generator (http://www.random.org).
Results
E2F1 expression accurately groups patients into good and
poor outcome groups
We sought to improve the capacity of a small number of
genes to correctly divide breast cancer patients into
good and poor prognosis groups. We started with a can-
didate gene approach, a methodology used in previous
studies [4]. We chose to begin with E2F1, as its tran-
script levels are reportedly prognostic in human breast
cancer [13], and because the E2F1 protein stimulates
tumor cell proliferation, a process that is inversely cor-
related with breast cancer patient survival [6,8,14-16].
We also imagined that genes whose expression
enhanced the prognostic power of E2F1 transcript levels
to predict patient survival, might uncover genes whose
products interacted directly or indirectly with E2F1.
To verify that E2F1 expression correlated with patient
survival in large microarray breast cancer datasets, we
made use of a database comprising a cohort of 295
breast cancer patients, whose tumors’ gene expression
profiles are known and for which clinical follow up data
is available [2]. We first divided these patients into E2F1
high and low expressing groups by calculating the aver-
age expression of E2F1 transcripts in the tumors of all
295 patients, and used the average expression value to
divide patients into high and low E2F1 expression
groups. The latter process led to assignment of 142
patients to the E2F1 high expression group, and 153
patients to the E2F1 low expression group (Figure 1A).
We considered overall survival as the endpoint for our
analyses. We next measured the differences in endpoint
between patients in the E2F1 high and low expressing
g r o u p s ,a n df o u n dt h a th i g hE2F1 transcript levels cor-
related with poor overall patient survival, whereas low
E2F1 transcript abundance was associated with a better
overall patient survival (Figure 1B, Log-rank, *p < 0.001,
Figure 1C, Hazard Ratio (HR): 3.49 (2.237-5.445)).
Because E2F1 transcript abundance alone was not
completely accurate at classifying patients into good
and poor prognosis groups, we sought to identify other
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power of E2F1 transcript levels. We first defined high,
average, and low E2F1 expression based on expression
above, within, or below the 95% confidence interval for
E2F1 expression among all 295 patients. We then took
a modified approach from that which we developed
previously [10] to find genes that were i) generally
highly expressed in tumors where high to average
E2F1 expression was indicative of poor patient survival,
a n di i )g e n e r a l l yw e r ee x p r e s s e da tl o wl e v e l si nt u m o r s
where high-average E2F1 expression was not associated
with poor patient survival. The mostly highly ranked
candidate among the 295 patient cohort was
KIAA0191, which is also commonly known as TUT4
or ZCCHC11 [11].
To learn whether KIAA0191 expression alone was
related to patient survival, we divided the patient cohort
into KIAA0191 high and low expressing groups, as
described above. This led to 154 patients being selected
for the KIAA0191 high expression group and 141
patients being selected for the low expression group
(Figure 2A). We compared survival between these two
groups and found that there was no statistically signifi-
cant difference in survival between the KIAA0191 high
and low expressing groups (Figure 2B, Log-rank, p >
0.05, Figure 1C, HR: 1.57 (0.995-2.405)). We next deter-
mined whether KIAA0191 transcript levels were related
to patient survival in the context of specific levels of
E2F1 expression. We divided the 295 patient cohort into
E2F1 high, average, and low expression groups as
described above. We then determined whether
KIAA0191 expression was related to patient survival in
various E2F1 expression level subgroups. We stratified
the patients within each E2F1 expression subgroup on
the basis of high and low KIAA0191 expression, and
compared survival of these patients. KIAA0191
transcript levels were related to patient survival in the
context of high and average E2F1 expression, but not
low E2F1 expression (Figure 2D-G, E2F1 high: Log-
rank, *p < 0.05, HR: 1.96 [1.16-3.308], E2F1 Medium:
Log-rank, *p < 0.05, HR: 6.6 [1.36-32.78], E2F1 Low:
Log-rank, p > 0.05 HR: 0.55 [0.19-1.573]).
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Figure 1 E2F1 expression groups patients into good and poor overall survival groups. A) Selection for the E2F1 high expression group
and the E2F1 low expression group. B & C) Differences in endpoint between patients in the E2F1 high and low expression groups, where high
E2F1 expression correlated with poor overall patient survival and low E2F1 expression was associated with a better overall patient survival.
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prognosis decision-making
Because we found that KIAA0191 expression was only
predictive of patient survival in the context of E2F1
transcript levels, we devised a tree-based decision strat-
egy to integrate KIAA0191 expression into our model of
using E2F1 transcript abundance to separate breast
cancer patients into good and poor prognosis groups
(Figure 3A). Because KIAA0191 expression was not
linked to patient survival in E2F1 low expressing
patients, and these patients had good overall survival,
we grouped patients with low E2F1 expression directly
into the low risk group (Figure 3B&3C, LOW RISK:
Log-rank [High vs Low], *p < 0.0001 HR: 10.2 [5.50-
18.91], Log-rank [Med vs Low], *p < 0.0001 HR: 4.31
[2.22-8.40]). However, when the patient’st u m o r
expressed either high or average E2F1 transcript levels,
we also used KIAA0191 expression levels to classify
these patients among the various risk groups. Patients
whose tumors expressed E2F1 transcripts of average
abundance and transcripts of KIAA0191 at low or high
levels where divided into low or medium risk groups,
respectively, whereas patients whose tumors expressed
E2F1 transcripts at high levels and that of K1AA0191 at
either low or high KIAA0191 levels were grouped into
medium and high risk groups, respectively (Figure
3B&3C, MEDIUM RISK: Log-rank [High vs Med], *p =
0.021 HR: 1.81 [1.10-2.99], Log-rank [Med vs Low], *p <
0.0001, HR: 4.31 [2.22-8.40], HIGH RISK: Log-rank
[High vs Low], *p < 0.0001 HR: 10.2 [5.50-18.91]. To
assess the predictive accuracy of E2F1/KIAA0191, we
calculated Harrell’s C-index [12]. In this fashion, a C-
index value of 0.5 indicates predictive performance
which is no better than chance, whereas values greater
than 0.5 indicate true predictive capacity. We calculated
Harrell’s C-index for two different comparisons, where
</Ϭϭϵϭ ,ŝŐŚ </Ϭϭϵϭ >Žǁ
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dŽƚĂůƉĂƚŝĞŶƚƐ ϭϱϰ ϭϰϭ
ĞĂƚŚƐ ϰϵ ϯϬ
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ĞĂƚŚƐ ϯϳ ϮϬ ϱ Ϯ ϳ ϴ
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'
Figure 2 KIAA0191 expression is not prognostic when used alone, but is prognostic in the context of average to high E2F1
expression. A) KIAA0191 expression for all patients B & C) Survival comparison between the KIAA0191 high expression group and the KIAA0191
low expression group; there was no survival difference between the KIAA0191 high and low E2F1 expressing groups. D-G) KIAA0191 expression
in relation to patient survival in the context of specific levels of E2F1 expression. Patient population divided into E2F1 high, average, and low
expression groups, then KIAA0191 expression was measured and related to patient survival in each group.
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low risk patients (Harrell’s C-index: 0.75), and predicted
high and medium risk patients to predicted low risk
patients (Harrell’s C-index: 0.71). In both cases, the
C-index values were greater than 0.5 indicating true pre-
dictive performance of our E2F1/KIAA0191 signature.
We also tested whether KIAA0191 expression was
prognostic in the context of the expression 2 other
genes, Aurora kinase A (AURKA)a n dBUB1,w h i c h
like E2F1, are independently prognostic (data not
shown) and linked to cell proliferation [17-20]. We
found that grouping patients into high, medium and
low risk groups (as described above), by interchanging
either AURKA or BUB1 transcript levels for that of
E2F1, resulted in highly similar risk grouping as
observed with E2F1 expression (Figure 4A-E). Taken
together, these results suggest that the relationship
observed between KIAA0191 and E2F1 is also shared
between KIAA0191 and other proliferation-associated
genes.
Discussion
Prognostic tests, which identify high and low risk cases
of breast cancer, are greatly beneficial for identifying
patients who can be spared unnecessary chemotherapy.
For example, several clinical trials, including the
National Surgical Adjuvant Breast and Bowel Project
trials B-14 and B-20, have shown that adding che-
motherapy to tamoxifen treatment increases survival in
node-negative, estrogen-receptor-positive breast cancer
patients [21-23]. However, the 10 year recurrence rate
with tamoxifen treatment alone is only 15%, therefore if
all patients were to equally receive additional che-
motherapy, it would result in 85% of patients receiving
little chemotherapy-derived benefit but nonetheless suf-
fering its deleterious side effects.
In attempt to spare patients unnecessary chemother-
apy, treatment decisions have traditionally been made
based primarily on classical histopathological and immu-
nohistochemical techniques. However, within the last
several years, many genomic based molecular signatures

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
Figure 3 KIAA0191 and E2F1 expression can be combined to accurately group patients into low, medium and high risk groups.A )
Tree-based decision strategy to integrate KIAA0191 expression into our model of using E2F1 expression to separate breast cancer patients into
good and poor prognosis groups. B) % survival over time for low, medium and high risk patients. Patients with low E2F1 expression group
directly into the low risk group, however, when patients had either high or average E2F1 expression we also used KIAA0191 expression to
classify these patients among the various risk groups. Patients with average E2F1 expression and either low or high KIAA0191 expression where
grouped into low and medium risk groups, respectively, whereas patients with high E2F1 expression and either low or high KIAA0191 expression
were grouped into medium and high risk groups. C) Patients who survived or succumbed to breast cancer for each risk group, as well as
associated hazard ratios between risk groups.
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tumor tissue to breast cancer recurrence [2-5]. Impor-
tantly, many of these gene signatures more accurately
assign risk to breast cancer patients than conventional
criteria. However, a practical limitation of these signa-
tures is that assays of transcript abundance require rela-
tively intact RNA, as well as expensive equipment and
technical expertise, which is unavailable in most hospital
pathology laboratories. Hence, tumor specimens are
commonly shipped to specialized clinical laboratories
thereby increasing the turn-around time and cost of
these tests. For these reasons, we sought to determine
whether we could generate relatively small gene signa-
tures (2-3 genes), which might yield accurate prognostic
information. Indeed, a signature comprising 2-3 genes
might be developed into an immunohistochemistry
assay, which could be carried out in hospital-based
pathology laboratories thereby saving both time and
cost.
We began our experiments by choosing a single gene
using a candidate gene approach. Because tumor cell
proliferation is linked to poor survival in breast cancer
patients, we first tested whether the expression of the
single “proliferation” gene, E2F1, was also linked to sur-
vival in breast cancer patients [5,6,8,9,15,16,18]. The
observation that high expression of E2F1 transcripts
indicated poor overall patient survival in the dataset
used for this study is unsurprising, given that tumor cell
proliferation is associated with poor patient survival in
other large breast cancer patient datasets, and low E2F1
transcript levels have previously been linked to good
patient survival [13,18].
We next sought to identify additional genes whose
expression might augment the predictive accuracy of E2F1
 
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Figure 4 KIAA0191 expression is also prognostic in the context of AurKA expression. A) Tree-based decision strategy to integrate
KIAA0191 expression into our model using the expression of a proliferation gene to separate breast cancer patients into good and poor
prognosis groups. B & C) % Survival over time for low, medium and high risk patient groups, as well as D & E) associated hazard ratios between
risk groups.
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might be developed. Indeed, such genes would be useful
for increasing the accuracy of genomic based clinical out-
come predictors, as well as understanding E2F1 based pro-
liferation programs in breast cancer cells. Our analyses
revealed that KIAA0191 transcript abundance could be
used in the context of average to high levels of E2F1 tran-
scripts to more precisely predict breast cancer patient sur-
vival. However, in the context of low E2F1 transcript
levels, KIAA0191 expression was not linked to patient out-
come. These results suggest that there is a relationship
between E2F1 and KIAA0191 expression, which is predic-
tive of patient outcome, and that there is a likely comple-
mentary involvement of both genes in breast cancer
progression. Importantly, the observation that the expres-
sion of other proliferation genes, such as AURKA [18,20],
BUB1 [17,19,24] could be used to replace E2F1,s u g g e s t s
that the relationship of KIAA0191 expression to patient
survival is linked to cell proliferation. Indeed, these obser-
vations highlight that there is a potentially novel functional
relationship between cell proliferation and KIAA0191.
Indeed, this relationship appears to be important for the
pathogenesis of breast cancer and is a topic that warrants
further investigation.
Using the data available for this study it wasn’t possi-
ble to measure the exact predictive accuracy of our 2-
gene signature in an unbiased manner. From our initial
analyses the predictive power of the E2F1/KIAA0191 2-
gene signature looks quite promising (High vs Low, HR:
10.2 [5.5-18.9], Harrell’s C-index: 0.75, Medium vs Low,
HR: 4.3 [2.2-8.4], Harrell’s C-index: 0.71), however
future studies will need to replicate these findings using
independent gene expression data sets.
An advantage of our 2-gene signature over currently
available prognostic signatures is that it may be suitable
for development as an immunohistochemical based test.
As mentioned previously, immunohistochemical based
tests are faster, cheaper, and have greater availability to
patients, than the currently available mRNA based tests.
Furthermore, antibodies that `recognize E2F1 and
KIAA0191 are commercially available, and several pro-
tocols exist for the quantification of protein expression
using immunohistochemistry [25]. However, there are
significant differences in the technology platforms used
for gene and protein expression assays (differences in
dynamic range, linearity of relationship to clinical out-
come), and therefore, genes which perform well using
mRNA based expression profiling technology may/may
not perform as well using a protein expression based
immunohistochemical test [26]. Beyond this issue, the
exact correlation between mRNA and protein expression
remains poorly studied, although some initial work sug-
gests that the correlation is significant [27]. As a result,
i ti si m p o r t a n tt on o t et h a tt h i sa s p e c to fo u rs t u d y
remains largely theoretical, as it is unclear how well
such an immunohistochemical test would work for
patient prognosis. To this end, validation of the 2-gene
signatures using immunohistochemistry is a major focus
of our current studies.
A major implication of this study is that it is impor-
tant to understand the context in which a gene’s expres-
sion is most highly related to patient survival. For
example, we observed that high E2F1 expression was
most related to poor patient outcome when that
patient’s tumor also expressed high levels of KIAA0191.
When KIAA0191 was not expressed at high levels, the
relationship between high E2F1 transcript levels and
poor outcome was significantly reduced. In line with
these observations, average levels of E2F1 expression
were associated with poor patient outcome when
KIAA0191 w a sh i g h l ye x p r e s s e d ,a n dg o o dp a t i e n to u t -
come when KIAA0191 was expressed at low levels.
Indeed, we took advantage of this relationship to gener-
ate a 2-gene based decision tree, which made highly
accurate predictions about patient outcome, while only
taking into account the expression of 2 genes.
Conclusion
We envision that the identification of gene signatures,
which are highly predictive, but consist of relatively few
genes (2-3 genes), would allow the use of immunohisto-
chemical or immunofluorescent based assays that are
commonly used in hospital-based pathology laboratories
to readily guide the use of chemotherapeutics in breast
cancer patients. Importantly, immunohistochemical or
immunofluorescent testing does not require long dis-
tance transfer of tumor samples to molecular profiling
facilities (as is the case for MammaPrint™ and Onco-
type DX) and thus would provide a less time-consuming
and less costly means of providing prognostic informa-
tion to breast cancer patients.
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